OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical Pharmacology & Therapeutics is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Sodium Bicarbonate Prescription and Extracellular Volume Increase: Real‐world Data Results from the AlcalUN Study	499
Return to SENDer: The Submitted Electronic Data for Nonclinical Cardiovascular Studies is Not Facilitating Transparency, Translation or Innovation	283
Issue Information	228
In This Issue	193
ASCPT News	185
In This Issue	126
In this Issue	112
Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors	108
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease	105
	102
French‐Speaking Network of Pharmacogenetics (RNPGx) Recommendations for Clinical Use of Mavacamten	93
Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies	87
Model‐Informed Selection of the Recommended Phase 2 Dosage for Anti‐TIGIT Immunotherapy Leveraging co‐Expressed PD‐1 Inhibitor Target Engagement	84
Factors Influencing Medication Adherence in Heart Failure Patients—A Survey Among Cardiac Healthcare Providers	84
Integrated Evidence Planning for Enhancing Patient Care: Harnessing the Power of Real‐World Evidence	83
Chinese Expert Consensus on the Clinical Diagnosis and Management of Statin Intolerance	69
Methodological Insights on Biomarker‐Based Patient Selection: A Review of Scientific Advice Procedures at the European Medicines Agency	69
PharmVar GeneFocus: CYP3A5	64
US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience	64
Pharmacogenomic Prescribing Guidelines: Are They Always Useful?	62
Using Machine Learning to Determine a Suitable Patient Population for Anakinra for the Treatment of COVID‐19 Under the Emergency Use Authorization	61
ICH S7B In Vitro Assays Do Not Address Mechanisms of QT_C Prolongation for Peptides and Proteins – Data in Support of Not Needing Dedicated QT_C Studies	59
Nicotine Metabolite Ratio Decreases After Switching Off Efavirenz‐Based Therapy in People With HIV Who Smoke	56
Progress in Clinical Pharmacology in China: A Randomized Controlled Study to Advance Genotype‐Guided Precision Medicine	56
Machine Learning‐Led Optimization of Combination Therapy: Confronting the Public Health Threat of Extensively Drug Resistant Gram‐Negative Bacteria	55

A Randomized Trial Comparing Standard of Care to Bayesian Warfarin Dose Individualization	52
Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov	52
Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling	51
Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned	50
Protecting the Kidney: The Unexpected Logic of Inhibiting a Glucose Transporter	49
Effect of CYP3A5 and CYP3A4 Genetic Variants on Fentanyl Pharmacokinetics in a Pediatric Population	48
More Than Pharmacokinetics: Transporters in Clinical Pharmacology	47
Estimating Culprit Drugs for Adverse Drug Reactions Based on Bayesian Inference	46
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective	45
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review	45
Reply to “Interpretation of Pharmacovigilance Disproportionality Analyses”	45
Reply to “Questioning Bayesian Inference‐Based Models for Estimating Culprit Drugs for Adverse Drug Reactions”	45
DrugWAS: Drug‐wide Association Studies for COVID‐19 Drug Repurposing	44
Enhancing External Control Arm Analyses through Data Calibration and Hybrid Designs	42
Promoting Clinical Trial Diversity: A Highlight of Select US FDA Initiatives	40